Identification of CD4CD25CD127 Regulatory T Cells and CD14HLADR/low Myeloid-derived Suppressor Cells and Their Roles in the Prognosis of Breast Cancer

Overview

Journal Biomed Rep

Specialty Biochemistry

Date 2016 Jul 23

PMID 27446543

Citations 17

Authors

Jinhu Wang

Jianhong Yang

Affiliations

Soon will be listed here.

Abstract

The aim of the present study was to identify cluster of differentiation 4 (CD4)CD25CD127 regulatory T cells (Tregs) and CD14 human leukocyte antigen-antigen D-related (HLADR)/low myeloid-derived suppressor cells (MDSCs) in patients with breast cancer of varying stages, and investigate their roles and the potential interactions in the prognosis of breast cancer. A total of 40 patients with breast cancer were included in the study. A total of 30 healthy individuals served as the healthy control. Flow cytometry was performed for the identification of biomarkers. Natural Tregs were characterized by the expression of CD4CD25CD127. The MDSC frequency was expressed as the percentage of CD33CD11bHLADRlineage markers (Lin). The absolute number of Tregs was higher in breast cancer patients compared to the healthy control. The absolute number of Tregs in the patients with stage III or IV breast cancer was higher than those of the stage I or II, respectively. The percentage showed a gradual increase in the patients with breast cancer compared with the normal control. No direct correlation was established between the number or percentage of Tregs and the patient survival. There was a higher percentage of circulating MDSCs in breast cancer patients compared with the normal individuals. A close correlation was established between clinical cancer stage and percentage and total number of circulating MDSCs. To be exact, a significant increase of MDSC percentage and total number was observed in patients with stage III-IV breast cancer compared with the other cancer patients (stage I-II) and the normal individuals. No statistical difference was observed in the 3- and 5-year survival rates in the breast cancer patients with enhanced expression of Tregs, compared with the normal individuals. In conclusion, enhanced expression of CD4CD25CD127 Tregs cells and CD33CD11HLADRLIN MDSCs were identified from patients with breast cancer. Patients with advanced stage breast cancer showed upregulation of such cells. However, these 2 types of cells showed no correlation with the prognosis of breast cancer.

Citing Articles

Leveraging the Dynamic Immune Environment Triad in Patients with Breast Cancer: Tumour, Lymph Node, and Peripheral Blood.

Wall I, Boulat V, Shah A, Blenman K, Wu Y, Alberts E Cancers (Basel). 2022; 14(18).

PMID: 36139665 PMC: 9496983. DOI: 10.3390/cancers14184505.

Clinical Significance of Negative Costimulatory Molecule PD-1/PD-L1 on Peripheral Blood Regulatory T Cell Levels among Patients with Pulmonary Tuberculosis.

Yang C, Dai F, Pulati R, Jiao Y, Xu Q J Trop Med. 2022; 2022:7526501.

PMID: 36035072 PMC: 9410994. DOI: 10.1155/2022/7526501.

Peripheral Blood Mononuclear Cell Populations Correlate with Outcome in Patients with Metastatic Breast Cancer.

Larsson A, Nordstrom O, Johansson A, Ryden L, Leandersson K, Bergenfelz C Cells. 2022; 11(10).

PMID: 35626676 PMC: 9139201. DOI: 10.3390/cells11101639.

The Role of Myeloid-Derived Suppressor Cells in Tumor Growth and Metastasis.

Bayik D, Lee J, Lathia J Exp Suppl. 2022; 113:189-217.

PMID: 35165865 DOI: 10.1007/978-3-030-91311-3_7.

Mechanisms Underlying the Role of Myeloid-Derived Suppressor Cells in Clinical Diseases: Good or Bad.

Ge Y, Cheng D, Jia Q, Xiong H, Zhang J Immune Netw. 2021; 21(3):e21.

PMID: 34277111 PMC: 8263212. DOI: 10.4110/in.2021.21.e21.

References

Filipazzi P, Huber V, Rivoltini L . Phenotype, function and clinical implications of myeloid-derived suppressor cells in cancer patients. Cancer Immunol Immunother. 2011; 61(2):255-263. PMC: 11029611. DOI: 10.1007/s00262-011-1161-9. View

Hein F, Massin F, Cravoisy-Popovic A, Barraud D, Levy B, Bollaert P . The relationship between CD4+CD25+CD127- regulatory T cells and inflammatory response and outcome during shock states. Crit Care. 2010; 14(1):R19. PMC: 2875534. DOI: 10.1186/cc8876. View

Srivastava M, Bosch J, Thompson J, Ksander B, Edelman M, Ostrand-Rosenberg S . Lung cancer patients' CD4(+) T cells are activated in vitro by MHC II cell-based vaccines despite the presence of myeloid-derived suppressor cells. Cancer Immunol Immunother. 2008; 57(10):1493-504. PMC: 2805175. DOI: 10.1007/s00262-008-0490-9. View

Ramsdell F . Foxp3 and natural regulatory T cells: key to a cell lineage?. Immunity. 2003; 19(2):165-8. DOI: 10.1016/s1074-7613(03)00207-3. View

Adegboyega T, Landercasper J, Linebarger J, Johnson J, Andersen J, Dietrich L . Institutional review of compliance with NCCN guidelines for breast cancer: lessons learned from real-time multidimensional synoptic reporting. J Natl Compr Canc Netw. 2015; 13(2):177-83. DOI: 10.6004/jnccn.2015.0026. View

Mizukami Y, Kono K, Kawaguchi Y, Akaike H, Kamimura K, Sugai H . Localisation pattern of Foxp3+ regulatory T cells is associated with clinical behaviour in gastric cancer. Br J Cancer. 2007; 98(1):148-53. PMC: 2359685. DOI: 10.1038/sj.bjc.6604149. View

Ulmer A, Scholz W, Ernst M, Brandt E, Flad H . Isolation and subfractionation of human peripheral blood mononuclear cells (PBMC) by density gradient centrifugation on Percoll. Immunobiology. 1984; 166(3):238-50. DOI: 10.1016/S0171-2985(84)80042-X. View

Gilboa E . The risk of autoimmunity associated with tumor immunotherapy. Nat Immunol. 2001; 2(9):789-92. DOI: 10.1038/ni0901-789. View

Allan S, Crome S, Crellin N, Passerini L, Steiner T, Bacchetta R . Activation-induced FOXP3 in human T effector cells does not suppress proliferation or cytokine production. Int Immunol. 2007; 19(4):345-54. DOI: 10.1093/intimm/dxm014. View

10.

Hezova R, Slaby O, Faltejskova P, Mikulkova Z, Buresova I, Muthu Raja K . microRNA-342, microRNA-191 and microRNA-510 are differentially expressed in T regulatory cells of type 1 diabetic patients. Cell Immunol. 2009; 260(2):70-4. DOI: 10.1016/j.cellimm.2009.10.012. View

11.

Liu W, Putnam A, Xu-Yu Z, Szot G, Lee M, Zhu S . CD127 expression inversely correlates with FoxP3 and suppressive function of human CD4+ T reg cells. J Exp Med. 2006; 203(7):1701-11. PMC: 2118339. DOI: 10.1084/jem.20060772. View

12.

Nagaraj S, Gabrilovich D . Myeloid-derived suppressor cells in human cancer. Cancer J. 2010; 16(4):348-53. DOI: 10.1097/PPO.0b013e3181eb3358. View

13.

Zhang B, Wang Z, Wu L, Zhang M, Li W, Ding J . Circulating and tumor-infiltrating myeloid-derived suppressor cells in patients with colorectal carcinoma. PLoS One. 2013; 8(2):e57114. PMC: 3577767. DOI: 10.1371/journal.pone.0057114. View

14.

Poschke I, Mougiakakos D, Hansson J, Masucci G, Kiessling R . Immature immunosuppressive CD14+HLA-DR-/low cells in melanoma patients are Stat3hi and overexpress CD80, CD83, and DC-sign. Cancer Res. 2010; 70(11):4335-45. DOI: 10.1158/0008-5472.CAN-09-3767. View

15.

Sakaguchi S . Naturally arising Foxp3-expressing CD25+CD4+ regulatory T cells in immunological tolerance to self and non-self. Nat Immunol. 2005; 6(4):345-52. DOI: 10.1038/ni1178. View

16.

Nagaraj S, Gabrilovich D . Myeloid-derived suppressor cells. Adv Exp Med Biol. 2007; 601:213-23. DOI: 10.1007/978-0-387-72005-0_22. View

17.

Lindau D, Gielen P, Kroesen M, Wesseling P, Adema G . The immunosuppressive tumour network: myeloid-derived suppressor cells, regulatory T cells and natural killer T cells. Immunology. 2012; 138(2):105-15. PMC: 3575763. DOI: 10.1111/imm.12036. View

18.

Diaz-Montero C, Salem M, Nishimura M, Garrett-Mayer E, Cole D, Montero A . Increased circulating myeloid-derived suppressor cells correlate with clinical cancer stage, metastatic tumor burden, and doxorubicin-cyclophosphamide chemotherapy. Cancer Immunol Immunother. 2008; 58(1):49-59. PMC: 3401888. DOI: 10.1007/s00262-008-0523-4. View

19.

Lechner M, Megiel C, Russell S, Bingham B, Arger N, Woo T . Functional characterization of human Cd33+ and Cd11b+ myeloid-derived suppressor cell subsets induced from peripheral blood mononuclear cells co-cultured with a diverse set of human tumor cell lines. J Transl Med. 2011; 9:90. PMC: 3128058. DOI: 10.1186/1479-5876-9-90. View

20.

Mehta P . Potential role of platelets in the pathogenesis of tumor metastasis. Blood. 1984; 63(1):55-63. View